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Modiﬁed Rodnan skin score
a  b  s  t  r  a  c  t
Systemic sclerosis (SSc) is a chronic autoimmune disease with a high morbidity and mortal-
ity.  Although cyclophosphamide is effective for severe and refractory cases, there is demand
for  new treatments. The biological treatment with B-cell depletion with rituximab (RTX) has
demonstrated efﬁcacy for this demand in open-label studies.
Objective: This study was conducted with the aim to retrospectively evaluate all patients
who used RTX for the treatment of SSc in our center.
Patients and methods: We  retrospectively evaluated medical records of all patients with SSc
who used RTX to treat this disease from January 2009 to January 2015. Systemic, cutaneous,
and  pulmonary involvement data and laboratory results before and six months after the
ﬁrst  infusion of RTX were collected.
Results: Ten patients received treatment during the study period and were included in this
series.  All patients had a diffuse form of the disease. Five patients suffered from an early
(duration of disease shorter or equal to four years), rapidly progressive disease, and another
ﬁve received RTX at late stages of the disease. In both groups of patients, stabilization of the
pulmonary picture was observed, with a fall in the skin score in those patients with early
forms  of the disease.
Discussion: Similar to ﬁndings in previous studies, RTX was effective in treating early and
rapidly progressive forms of SSc. We also found that patients with long-term illness maybeneﬁt from the treatment.
©  2016 Published by Elsevier Editora Ltda. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).∗ Corresponding author.
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Tratamento  da  esclerose  sistêmica  com  rituximabe:  uma  série







r  e  s  u  m  o
A esclerose sistêmica (ES) é uma doenc¸a autoimune crônica de alta morbimortalidade.
Ainda que a ciclofosfamida seja eﬁcaz, para casos graves e refratários há demanda para
novos  tratamentos. A terapia biológica com deplec¸ão de células B com rituximabe (RTX)
demonstrou eﬁcácia para tal demanda em estudos abertos.
Objetivo: Avaliar retrospectivamente todos os pacientes que ﬁzeram uso do RTX para trata-
mento de ES em nosso centro.
Pacientes e métodos: Foram avaliados retrospectivamente todos os prontuários de pacientes
com  ES que ﬁzeram uso de RTX para tratamento da ES de janeiro de 2009 a janeiro de 2015.
Dados de acometimento sistêmico, cutâneo, pulmonar e laboratoriais antes e seis meses
após  a primeira infusão de RTX foram coletados.
Resultados: Dez pacientes receberam o tratamento no período de estudo e foram incluídos
na  presente série de casos. Todos os pacientes tinham a forma difusa da doenc¸a. Cinco
pacientes tinham formas iniciais (tempo de doenc¸a menor ou igual a quatro anos) e rapida-
mente progressiva da doenc¸a e cinco receberam o RTX em fases tardias da doenc¸a. Houve
estabilizac¸ão do quadro pulmonar em ambos os grupos de pacientes e reduc¸ão no escore
cutâneo nos pacientes com formas iniciais da doenc¸a.
Discussão: Similar ao encontrado em estudos prévios, o RTX foi eﬁcaz no tratamento de for-
mas  iniciais e rapidamente progressivas da ES. Veriﬁcamos também benefício em pacientes
com longa durac¸ão da doenc¸a.






























ystemic sclerosis (SSc) is a chronic systemic autoimmune
isease characterized by ﬁbrosis, generalized vasculopathy
nd autoimmunity. The vasculopathy is characterized by Ray-
aud’s phenomenon and pulmonary arterial hypertension.
ibrosis occurs mainly in the skin, causing sclerodactyly and
kin thickening; in the lungs, SSC produces a progressive and
rreversible interstitial lung disease.1,2
Pulmonary ﬁbrosis remains the leading cause of death in
Sc. Notwithstanding that the conventional treatment with
yclophosphamide has been shown to be effective, there were
o decreases in 5- and 10-year mortality and more  severe
orms of the disease may not respond to this treatment.3–5
t was also reported an improvement in skin involvement,
ssessed by the modiﬁed Rodnan skin score (mRSS); however,
here is a tendency for recurrence of the condition when the
herapy is discontinued.5 Cyclophosphamide is a highly-toxic
rug and shall not be used above a cumulative dose of 18 g.
hus, new therapies are in order for serious forms of SSc, espe-
ially in patients with extensive cutaneous and pulmonary
nvolvement.
Biological therapy has revolutionized the treatment of
ther autoimmune diseases such as rheumatoid arthritis
nd, more  recently, this therapeutic strategy has been proven
ffective in patients with systemic lupus erythematosus. In
heumatoid arthritis, the biological therapy, including anti-
NF agents, depletion of B-cells and anti-IL-6 agents, was
ffective in controlling disease activity and in decreasing the
adiographic progression.6 In patients with Granulomatosis BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
with Polyangiitis, the therapy with B-cell depletion with the
use of rituximab (RTX) was effective in inducing disease remis-
sion, with fewer side effects versus conventional therapy with
cyclophosphamide.7 Among immunobiological agents, RTX
has been the most widely used drug in other autoimmune
diseases, in addition to rheumatoid arthritis.
The possibility of the use of RTX in the treatment of severe
forms of SSc was considered after evidence that B lymphocytes
perform a pathogenic role in this disease. Active B lympho-
cytes were isolated from lung and skin biopsies from patients
with SSc.8,9 Lafyatis et al. demonstrated a reduction in cuta-
neous B cell inﬁltrates in SSc patients treated with RTX.10
In the face of biological evidence of effectiveness and
considering the need for a systemic therapy superior to
cyclophosphamide, the use of RTX was tested in open-label
series of patients with severe and early forms of SSc. Smith
et al. prospectively studied eight patients with less than two
years duration of the diffuse form of SSc treated with two
infusions of 1 g of RTX.11,12 There was a reduction in the mod-
iﬁed Rodnan skin score and in disease activity scores, and no
progression of diffuse interstitial pneumonitis was observed.
Bosello et al. studied two open-label series of patients with
a diffuse disease with less than three years duration and
achieved similar results.13,14 In Giuggioli et al. series of 10
cases, these authors achieved a signiﬁcant reduction of mRSS
in most patients.15 In a proof-of-concept study, RTX was supe-
rior to conventional treatment in eight patients.16 In the
Scleroderma Trials and Research (EUSTAR) database, ritux-
imab was superior to conventional treatment.17 Currently, an
ongoing prospective study is being conducted by EUSTAR. It is
the Rituximab in systemic sclerosis trial (RECOVER).18
 o l . 2460  r e v b r a s r e u m a t
Based on this evidence, RTX seems to be an alternative for
the treatment of severe forms of SSc. It is likely that data from
the RECOVER study will be useful for future guidance on this
therapy. This study was conducted in order to retrospectively
evaluate a series of patients with diffuse forms and with severe
cutaneous and/or organ involvement treated with RTX in our
center since 2009 to-date. Patients who received RTX with indi-
cation due to the severity of the impairment, regardless of
disease duration, were studied.
Patients  and  methods
All medical records of SSc patients who had been treated with
RTX with its ﬁrst infusion from January 2009 to January 2015
were retrospectively reviewed. In this study, patients were
included irrespective of indication of RTX and of the form of
the disease. Patients with other concomitant systemic autoim-
mune diseases were excluded. In our series, the outcomes
evaluated were safety and efﬁcacy of RTX in the treatment
of SSc. The treatment protocol was as follows: RTX 1 g IV fol-
lowed by a second infusion after 15 days. Data obtained before
and six months after the infusion of RTX were reviewed.
Demographic, clinical, laboratory and immunological
(including positivity, title and pattern of antinuclear antibod-
ies [ANA]) data were collected, as well as the presence of
speciﬁc antibodies against SSc.
The reason for an indication of RTX, prior use of immuno-
suppressants, and cumulative dose of cyclophosphamide
were evaluated. Laboratory data (erythrocyte sedimentation
rate – ESR), and skin activity and pulmonary function ﬁndings
were recorded before and six months after the infusion of RTX.
As a routine of the Infusion Center in the Rheumatology outpa-
tient clinic, patients are observed for drug safety parameters.
We checked the occurrence of any infusion reaction (allergic,
or of any other type, during infusion) and/or infection of any
origin.
Regarding the efﬁcacy of the drug, the parameters eval-
uated were mRSS and pulmonary function assessed by
pulmonary function tests (PFTs) before and after the infusion
of RTX. Cutaneous activity was assessed using mRSS in 17
body areas; the test was performed before and six months
after RTX, always by the same female examiner. Although
mRSS has been performed in a non-blind way, the eval-
uation was carried out with an interval of 6 months and
the examiner did not have access to the previous result. A
good intra-examiner reproducibility of mRSS, when applied
by an experienced examiner, was demonstrated; however, the
inter-examiner reproducibility has not been proven.19 In this
context, we  consider mRSS as a possibly reliable test only
when applied by an experienced examiner. Pulmonary activ-
ity was evaluated before and after the infusion of RTX through
PFTs and high-resolution computed tomography (HRCT). In
PFTs, forced vital capacity (FVC) and carbon monoxide dif-
fusing capacity (DLCO) were evaluated before and after the
infusion of RTX. HRCT reports were reviewed before and six
months after administration of RTX with the use of a qual-
itative score. The following rating scores were assigned: 1.
Normal; 2. The presence of a ground glass pattern; 3. The
presence of a ground glass pattern and bronchiectasis; 4. The 0 1 6;5 6(5):458–463
presence of a ground glass pattern, bronchiectasis and bron-
chiolectasis; 5. The presence of consolidation areas; 6. The
presence of honeycombing areas, or of pulmonary ﬁbrosis.20
The stabilization of lung function, in accordance with other
studies which evaluated the treatment of pulmonary ﬁbrosis
associated with SSc, was considered as a satisfactory response
to treatment.5,17 The protocol was approved by the Research
Ethics Committee of our hospital.
Statistical  analysis
For the analysis of continuous variables (with normal distri-
bution) of FVC and mRSS values, the Student t test was used.
We  considered as statistically signiﬁcant p values < 0.05.
Results
Ten patients, all of them with diffuse disease (nine female and
one male) received RTX for the treatment of severe manifesta-
tions of SSc during the study period. Table 1 summarizes the
clinical and immunological proﬁle, the indication of RTX and
laboratory, skin and lung activity data before and six months
after the treatment with RTX. The mean age was 38.3 ±
12 years; disease duration 6.6 ± 4.3 years, and mean cumula-
tive dose of cyclophosphamide 12.9 ± 5.2 g. All patients were
in concomitant use of an immunosuppressive agent; eight
patients were being medicated with azathioprine 2 mg/kg/day
and two used mycophenolate mofetil 2 g/day. No patient was
being treated with corticosteroids. Regarding the safety end-
point, no patient had an adverse event within 6 months after
the use of RTX.
We  identiﬁed patients with two types of proﬁles; the ﬁrst
type was that of patients with disease duration ≤4 years and
a fast pulmonary and/or skin involvement (patients 1–5). All
patients in this group showed a rapidly progressive clinical
picture and had been refractory to treatment with cyclophos-
phamide. Four of them had nucleolar ANA in high titers and
three patients were also positive for anti-topoisomerase I
(anti-Scl-70), typifying an immunological proﬁle prognostic of
a greater severity in most cases. Patients 1–3 suffered from
a severe skin condition (all with mRSS >14) and had been
refractory to prior therapy with cyclophosphamide. As to the
pulmonary picture, we  found that, although these 3 patients
did not exhibit a severe restrictive syndrome, all of them pro-
gressed to interstitial lung disease when under treatment with
cyclophosphamide. According to clinical records, patient 1 had
a history of FVC decrease, from 90 to 71; patients 2 and 3 had
a history of worsening in their HRCT score, from 1 to 4; in
all patients, this occurred during treatment with cyclophos-
phamide in the previous year. Patient 4 was suffering from
a severe restrictive syndrome, with maximum HRCT score
and mRSS = 51 even after cyclophosphamide therapy. Patient
5 showed a 10-point worsening in mRSS without the pres-
ence of a severe pulmonary involvement; however, she had
a myopathy with muscle weakness and high levels of mus-
cle enzymes. After therapy with RTX, patients 1–4 showed a
signiﬁcant reduction in mRSS. Patient 1 showed improvement
in her cutaneous lesions from leucomelanoderma. Patient 5



























Table 1 – Disease duration, indications, cumulative doses of cyclophosphamide, pulmonary function and laboratory data before and after treatment with rituximab.
Patient number Disease
duration













1. 1. F, 39 years 3 years Pulmonary disease
refractory to CTX
12 g 65/25 71/70 NA 4/4 21/14 Nucleolar 1:640 + aScl70
2. 2. F, 39 years 3 years Pulmonary and skin disease





16/20 85/84 NA 4/4 14/4 Nucleolar 1:320 + aScl 70
3. 3. F, 23 years, brown 4 years Pulmonary and cutaneous
disease refractory to CTX
12  g 15/5 90/90 NA 4/4 18/14 Nucleolar 1:640 + aScl70
4. 4. F, 56 years,
Caucasian
4 years Pulmonary and cutaneous
disease refractory to CTX
12  g 5/5 58/61 60/60 6/6 51/28 Nucleolar 1:160
5. 5. F, 50 years,
Caucasian
3 years Worsening of 10 points in
mRSS after maximum dose
of CTX
12  g 5/5 77/77 NA 3/3 18/16 1:160 ﬁnely stippled
6. 6. F, 38 years, AA 13 years Pulmonary function
worsening
12  g 45/10 40/40 6/NA 6/6 18/6 Nucleolar 1:320 + aScl-70
7. 7. F, 62 years,
Caucasian
10 years Pulmonary function
worsening
12  g 30/5 37/39 28/30 6/6 14/6 Nucleolar 1:320 + aScl-70
8. 8. M, 51 years,
Caucasian
13 years Pulmonary function
worsening
18  g 10/10 71/71 37/40 6/6 7/4 Nucleolar 1:160
9. 9. F, 34 years, brown 5 years Pulmonary function
worsening
12  g 15/10 66/65 NA 6/6 10/4 Nucleolar 1: 160 + aScl-70
10. 10. F, 37 years,
Caucasian 11.
6 years Signiﬁcant cutaneous
worsening
12  g 47/20 52/56 66/66 4/4 40/32 Nucleolar 1:640 + aScl-70
CTX, cyclophosphamide; RTX, rituximab; mRSS, modiﬁed Rodnan skin score; ANA, antinuclear factor; aScl-70, anti-topoisomerase I antibody; NA, not available.
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Table 2 – FVC (forced vital capacity) and mRSS (modiﬁed








FVC 66.4 (SD 17.9) 71.2 (SD 17.6) 0.38
mRSS 20.9 (SD 13.8) 12.8 (SD 9.8) 0.003aSD, standard deviation.
a Statistically signiﬁcant.
her myopathy, with a recovery of strength and normalization
of muscle enzymes. All patients showed stabilization of their
lung disease six months after RTX infusion, under the protocol
described in the study (Table 1).
As to patients in the second group (patients 6–10), RTX was
indicated due to a sharp worsening of their pulmonary or skin
condition, after a lapse of more  than four years of illness.
These patients had an immunological proﬁle of ANA with a
nucleolar pattern, and also with the presence of anti-Scl-70 in
four patients who,  despite this, showed a protracted evolution
of the disease, seemingly with a predominantly irreversible
ﬁbrosis (HRCT score = 6 in patients 6–9). The values of FVC%
and DLCO% were sharply reduced in patients 6, 7, 9 and 10. The
patient 8 showed a history of quick decrease in FVC% (from 80
to 71%) in the last year, even when he was taking mycopheno-
late mofetil, and with a cumulative dose of cyclophosphamide
of 18 g. mRSS was above 14 in only two patients, indicating also
a lower activity of skin disease. But these patients responded
well to treatment, with improvement in mRSS and reports of
improved exercise ability. There was no increase in the values
of FVC% and DLCO%, but all patients reported improvement
in dyspnea; and one female patient discontinued the use of
supplemental oxygen.
Considering the whole group of patients, a statistically
signiﬁcant improvement in mRSS was noted. There was no
signiﬁcant improvement in FVC, but a stabilization of lung
function did occur. Table 2 summarizes FVC and mRSS values
before and after treatment in all 10 patients.
Discussion
Our results suggest that, in agreement with previous stud-
ies, RTX is a safe and effective therapy for the treatment of
severe forms of SSc. We  found no improvement in FVC, DLCO or
HRCT; however, the stabilization of the patients’ lung disease
did occur. A signiﬁcant improvement was observed in skin
condition, according to the assessment by mRSS. Considering
that all patients had been medicated with high cumulative
doses of cyclophosphamide, RTX was an alternative to the
continuation of treatment. There were no infusion reactions
or infections within 6 months after the ﬁrst infusion. In this
context, the safety of treatment with RTX in patients with SSc
is one of the main results of our study.The ﬁrst group of patients in our study has a proﬁle similar
to patients in the studies of Smith et al., Bosello et al., Daoussis
et al., and Giuggioli et al. 11–15 These initial studies evaluated
series consisting of 10–20 patients in an open-label strategy. 0 1 6;5 6(5):458–463
These were patients with short-term disease and with rapidly
progressive forms, characterized by an extensive skin involve-
ment (mRSS > 14), with an incipient pulmonary disease, and
refractory to conventional treatment with cyclophosphamide.
Smith et al. also reported a sustained safety and efﬁcacy
after two years of follow-up.12 Also, according to the litera-
ture, our group of patients with this proﬁle showed a good
response to treatment with RTX, with a signiﬁcant decrease
of mRSS in most patients and with stabilization of lung
function in all female patients. It is possible that in this pop-
ulation of patients with early forms of the disease, RTX is
beneﬁcial in the long term in a role of a disease modifying
agent.
Giuggioli et al. reported improvement in other manifesta-
tions of SSc, such as leucomelanoderma and calcinosis.15 We
also found that one of our female patients showed improve-
ment in her leucomelanoderma and another patient improved
her myopathy. This result, although described in isolated
cases, is noteworthy since these manifestations are typically
refractory to all therapeutic arsenal. While not constituting
a life-threatening or serious organ damage risk, these man-
ifestations generate a huge esthetic and functional impact,
affecting the quality of life of patients.
In a review, McQueen and Solanki commented that
although the package insert of RTX does not indicate its use
in the treatment of SSc, the results of open-label studies are
encouraging.21 The authors argue that, given this evidence,
it may not be appropriate to wait for the results of con-
trolled studies to indicate the treatment with RTX in patients
exhibiting a more  severe proﬁle. In our study, we  included
patients with a more  severe disease and in a high-mortality
risk. According to the review, we speculated that the mortality
in our patients would be reduced with the introduction of RTX,
in anticipation of the publication of prospective controlled
studies.
More recently the results of the EUSTAR database, which
retrospectively assessed SSc patients treated with rituximab,
have been published.17 A greater number of patients (63
in 42 centers) and a control group of patients with similar
proﬁles and whose members received only a conventional
immunosuppressant treatment were included. An absolute
improvement of 25% in mRSS was observed in those patients
treated with RTX. Similar to our results, there was also an
improvement in patients living with long-term illness. These
data suggest that the beneﬁts are not exclusive to patients
with early forms of the disease. An improvement was also
noted in patients with more  than three years’ disease. In
EUSTAR patients treated with RTX, the authors observed
stabilization of lung function, based on an assessment by
pulmonary function tests. In the control group, a signiﬁcant
worsening of FVC was observed. Our study lacks a control
group; but the EUSTAR results conﬁrm our impression that,
in these patients, the stabilization of lung function corrobo-
rates its efﬁcacy. These results suggest that RTX may also be
used in patients with longer-duration forms and with more
serious organ damage. It is argued that in the early years of
this disease, it is possible that a spontaneous improvement
comes up, being difﬁcult to attribute the results to the drug.
However, in previous studies its patients had already proved to
be refractory to treatment during the ﬁrst year of disease with
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yclophosphamide. This outcome, coupled with the evidence
rom the EUSTAR database and from the Daoussis’ proof-of-
oncept study, suggests that the improvement should not be
ttributed to the natural history of the disease, but to the
harmacological treatment. This question shall be answered
ith the results of the RECOVER trial, that prospectively
ncludes a group of treatment with rituximab and a control
roup.18
However, our study has its limitations. It has a retrospective
esign, with the possibility of data loss. There is also the lack of
 control group, and we could not guarantee that the improve-
ent would have occurred, even in untreated patients. It was
ot possible to perform a volumetric quantitative assessment
f HRCT changes. The follow-up period was also relatively
hort; thus, it was not possible to assess whether there would
e better results in a longer term.
Further studies with the inhibition of B cells as a therapy for
Sc at earlier stages of the disease and with precise indications
re necessary and can change the course of this disease, with
ts high morbidity and mortality.
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